Contraindication of Astemizole with Erythromycin Due to Fatal Cardiac Arrhythmias

Interaction Mechanisms

Erythromycin is a potent inhibitor of CYP3A4, the enzyme that metabolizes astemizole to inactive products; inhibition leads to reduced clearance of astemizole. (Centers for Disease Control and Prevention) 1
When CYP3A4 is blocked by erythromycin, astemizole concentrations rise to toxic levels in the circulation. (European Society of Cardiology) 2
Both astemizole and erythromycin directly block cardiac HERG (IKr) potassium channels, which prolongs ventricular repolarization. (European Society of Cardiology) 2
The combined HERG blockade produces additive QT‑interval prolongation on the electrocardiogram. (European Society of Cardiology) 2

Co‑administration induces acquired long‑QT syndrome, markedly increasing the risk of torsades de pointes, a polymorphic ventricular tachycardia that can progress to ventricular fibrillation. (European Society of Cardiology) 2
Fatal cardiac arrests have been reported in patients receiving the astemizole‑erythromycin combination. (European Society of Cardiology) 2

The CDC and FDA explicitly list erythromycin + astemizole as an absolute contraindication because of the potential for life‑threatening arrhythmias. (Centers for Disease Control and Prevention) 1
The American Academy of Dermatology also classifies the erythromycin‑astemizole pairing as contraindicated in its dermatology practice guidelines. (American Academy of Dermatology) 3
Astemizole has been withdrawn from the market in most countries, including the United States, owing to its documented risk of fatal cardiac events. (European Society of Cardiology) 2
Erythromycin is likewise contraindicated with other QT‑prolonging agents such as terfenadine, cisapride, and pimozide, reflecting a class‑wide safety warning. (Centers for Disease Control and Prevention; American Academy of Dermatology) [1][3]

When an antibiotic is required in a patient taking astemizole, azithromycin is the preferred macrolide because it does not significantly inhibit CYP3A4 and has minimal impact on cardiac repolarization. (Centers for Disease Control and Prevention) 1

The Centers for Disease Control and Prevention recommends erythromycin typically requires four divided daily doses for 14 days 4
Erythromycin is an inhibitor of the cytochrome P450 enzyme system (CYP3A subclass) and has numerous drug interactions, according to the MMWR Recommendations and Reports 5

The MMWR Recommendations and Reports warns that erythromycin should not be administered with astemizole, cisapride, pimazole, or terfenadine due to risk of serious cardiovascular events 5
Both drugs can cause gastrointestinal side effects, but these are more frequent and severe with erythromycin, as reported by the MMWR Recommendations and Reports 6
Erythromycin has been associated with infantile hypertrophic pyloric stenosis (IHPS) in neonates, while azithromycin has not shown this association, according to the MMWR Recommendations and Reports 6, 7

The MMWR Recommendations and Reports recommends both drugs for respiratory tract infections, skin and soft tissue infections 4, 8
Azithromycin is preferred over erythromycin for infants aged <1 month due to the risk of IHPS with erythromycin, as stated by the MMWR Recommendations and Reports 6
Erythromycin requires a longer treatment course (14 days) for pertussis compared to azithromycin (5 days), according to the MMWR Recommendations and Reports 4